Literature DB >> 24262905

Limbic neuromodulation: implications for addiction, posttraumatic stress disorder, and memory.

Ausaf Bari1, Tianyi Niu, Jean-Philippe Langevin, Itzhak Fried.   

Abstract

Deep brain stimulation, a technique whereby electrodes are implanted into specific brain regions to modulate their activity, has been mainly used to treat movement disorders. More recently this technique has been proposed for the treatment of drug addiction, posttraumatic stress disorder (PTSD), and dementia. The nucleus accumbens, amygdala, and hippocampus, central nuclei within the limbic system, have been studied as potential targets for neuromodulation for the treatment of drug addiction, PTSD, and dementia, respectively. As the scope of neuromodulation grows to include disorders of mood and thought, new ethical and philosophic challenges that require multidisciplinary discussion and cooperation are emerging.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Addiction; Alzheimer; Deep brain stimulation; Dementia; Limbic system; Memory; Posttraumatic stress disorder

Mesh:

Year:  2013        PMID: 24262905      PMCID: PMC4445935          DOI: 10.1016/j.nec.2013.08.004

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  64 in total

1.  Proposals to trial deep brain stimulation to treat addiction are premature.

Authors:  Adrian Carter; Wayne Hall
Journal:  Addiction       Date:  2011-02       Impact factor: 6.526

Review 2.  Deep brain stimulation of the nucleus accumbens for the treatment of addiction.

Authors:  Ulf J Müller; Jürgen Voges; Johann Steiner; Imke Galazky; Hans-Jochen Heinze; Michaela Möller; Jared Pisapia; Casey Halpern; Arthur Caplan; Bernhard Bogerts; Jens Kuhn
Journal:  Ann N Y Acad Sci       Date:  2012-12-10       Impact factor: 5.691

3.  Chronic depression and drug addiction treated by stereotactic surgery.

Authors:  G Knight
Journal:  Nurs Times       Date:  1969-05-08

4.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

Review 5.  Outcomes of posttraumatic stress disorder.

Authors:  N Breslau
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

6.  Focal brain damage protects against post-traumatic stress disorder in combat veterans.

Authors:  Michael Koenigs; Edward D Huey; Vanessa Raymont; Bobby Cheon; Jeffrey Solomon; Eric M Wassermann; Jordan Grafman
Journal:  Nat Neurosci       Date:  2007-12-23       Impact factor: 24.884

7.  The regulation of adult rodent hippocampal neurogenesis by deep brain stimulation.

Authors:  Hiroki Toda; Clement Hamani; Adrian P Fawcett; William D Hutchison; Andres M Lozano
Journal:  J Neurosurg       Date:  2008-01       Impact factor: 5.115

8.  Hippocampal atrophy predicts conversion to dementia after STN-DBS in Parkinson's disease.

Authors:  Selma Aybek; Francois Lazeyras; Aline Gronchi-Perrin; Pierre R Burkhard; Jean-Guy Villemure; Francois J G Vingerhoets
Journal:  Parkinsonism Relat Disord       Date:  2009-04-05       Impact factor: 4.891

Review 9.  Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: the search for a valid target.

Authors:  Nir Lipsman; Joseph S Neimat; Andres M Lozano
Journal:  Neurosurgery       Date:  2007-07       Impact factor: 4.654

10.  Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study.

Authors:  M P Laakso; K Partanen; P Riekkinen; M Lehtovirta; E L Helkala; M Hallikainen; T Hanninen; P Vainio; H Soininen
Journal:  Neurology       Date:  1996-03       Impact factor: 9.910

View more
  1 in total

Review 1.  Deep brain stimulation for the treatment of drug addiction.

Authors:  Tony R Wang; Shayan Moosa; Robert F Dallapiazza; W Jeffrey Elias; Wendy J Lynch
Journal:  Neurosurg Focus       Date:  2018-08       Impact factor: 4.047

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.